Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies. The company specializes in the discovery, development, and commercialization of drugs targeting nuclear export proteins for the treatment of cancer and other significant diseases. Its flagship product, XPOVIO® (selinexor), is a first-in-class, oral exportin 1 (XPO1) inhibitor and is approved in the U.S. for multiple oncology indications. These include combination therapies with Velcade® (bortezomib) and dexamethasone for multiple myeloma, as well as treatments for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Recent achievements highlight the company's commitment to advancing its late-stage clinical pipeline. Notably, Karyopharm has been at the forefront in evaluating selinexor's efficacy in combination therapies for multiple myeloma, endometrial cancer, and myelofibrosis. The company recently reported long-term follow-up data from a Phase 1/3 study on selinexor in combination with ruxolitinib in myelofibrosis patients, showing promising results in spleen volume and symptom reduction.
Financially, Karyopharm reported total revenue of $33.7 million for Q4 2023, with a full-year revenue of $146.0 million. Despite a competitive market, the company managed to maintain steady growth and focused resources on its high-potential pipeline. With a cash position of $192.4 million as of December 31, 2023, Karyopharm is well-positioned to continue its innovative research and development efforts.
Karyopharm's collaborations with global partners, including Antengene, Menarini, Neopharm, and FORUS, have extended the reach of XPOVIO to various international markets such as Europe, China, South Korea, and Israel. This international expansion underscores the global demand for innovative cancer therapies.
For more information, please visit www.karyopharm.com.
Karyopharm Therapeutics (Nasdaq: KPTI) has granted 8,800 restricted stock units (RSUs) to three newly-hired employees as of June 30, 2024, under its 2022 Inducement Stock Incentive Plan.
The RSUs are an inducement for employment and will vest over three years, with one-third vesting on each anniversary of the grant date. These awards are subject to the employees' continued service. Additionally, full vesting will occur if employment is terminated for 'good reason' or without 'cause' within one year following a change in control event.
Karyopharm Therapeutics, a commercial-stage pharmaceutical company, announced the grant of 9,500 restricted stock units (RSUs) to three newly-hired employees and 200,000 RSUs to Dr. Michael Method, Senior VP of Clinical Development. These grants, effective May 31, 2024, were made under the 2022 Inducement Stock Incentive Plan and follow Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over three years, contingent on continued employment. Immediate full vesting occurs if employment is terminated for 'good reason' or without 'cause' within one year of a 'change in control event.' Keywords: KPTI, Karyopharm, RSUs, Nasdaq, restricted stock units.
Karyopharm Therapeutics presented updated subgroup analyses from the SIENDO study at the 2024 ASCO Meeting, focusing on advanced or recurrent TP53 wild-type endometrial cancer. Key findings include a median progression-free survival (PFS) of 28.4 months for selinexor-treated patients versus 5.2 months for the placebo group. Additionally, a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis showed a mean of 26 months for selinexor compared to 15 months for placebo. No new safety signals were identified. The exploratory subgroup analysis highlighted promising efficacy signals, with ongoing Phase 3 trials expected to provide definitive results by mid-2025.
Karyopharm Therapeutics (Nasdaq: KPTI) announced that its senior management will participate in the Jefferies Global Healthcare Conference on June 5, 2024, in New York. The event includes a fireside chat at 1:00 p.m. ET. A live webcast and slides will be available on the company's website under the 'Events & Presentations' section and for replay afterward.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will participate in the 2024 RBC Capital Markets Global Healthcare Conference with a fireside chat on May 15. The live webcast can be accessed on the company's website.
Karyopharm Therapeutics Inc. announced significant refinancing transactions, extending the vast majority of its debt maturities to 2028 and 2029. The company exchanged $148.0 million of existing convertible notes due in 2025 for $111.0 million of new convertible notes due in 2029 and warrants. Additionally, a new $100.0 million senior secured term loan was issued, repaying principal portions and amending a royalty agreement with HealthCare Royalty. These transactions fortify the company's balance sheet and enhance its ability to unlock the potential of selinexor.
Karyopharm Therapeutics Inc. reported first-quarter 2024 financial results, highlighting revenue of $33.1 million, with $26.0 million from U.S. XPOVIO net product revenue. The company reaffirmed its full-year revenue guidance of $140.0 million to $160.0 million, including U.S. XPOVIO net product revenue guidance of $100.0 million to $120.0 million. Karyopharm made significant refinancing transactions and amended a royalty agreement to extend debt maturities into 2028 and 2029, strengthening its position for future growth. The company also presented data from the Phase 3 SIENDO trial of Selinexor maintenance treatment in endometrial cancer patients at the 2024 ASCO Annual Meeting.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will report its first quarter 2024 financial results on May 8, 2024. The management team will host a conference call and audio webcast to discuss the financial results and other updates. Investors can access the call and webcast through the company's website.
Karyopharm Therapeutics Inc. granted 72,700 restricted stock units (RSUs) to five new employees on April 30, 2024, under the 2022 Inducement Stock Incentive Plan. These RSUs will vest over three years, with 33 1/3% vesting annually. The awards are subject to continued service and can be fully exercisable in case of a 'change in control event' within the first year.
FAQ
What is the current stock price of Karyopharm Therapeutics (KPTI)?
What is the market cap of Karyopharm Therapeutics (KPTI)?
What is Karyopharm Therapeutics' main focus?
What is XPOVIO® (selinexor)?
What recent achievements has Karyopharm reported?
Who are Karyopharm's global partners?
What are Karyopharm's financial highlights?
What are the key indications for XPOVIO?
What is the significance of Karyopharm's research on nuclear export proteins?
How does Karyopharm support clinical trials and research?
What are the safety considerations for XPOVIO?
How can I get more information about Karyopharm's products or clinical trials?
